Design Therapeutics, Inc. DSGN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $58.13M+16.4% | $59.13M+33.3% | $57.86M+33.9% | $55.15M+23.7% | $49.93M-2.4% | ||
| $20.62M+11.6% | $20.34M+12.8% | $20.13M+14.3% | $19.78M+5.2% | $18.48M-6.7% | ||
| $78.76M+15.1% | $79.47M+27.4% | $77.99M+28.3% | $74.93M+18.2% | $68.4M-3.6% | ||
| -$78.76M-15.1% | -$79.47M-27.4% | -$77.99M-28.3% | -$74.93M-18.2% | -$68.4M+3.6% | ||
| —— | —— | —— | —— | —— | ||
| -$69.71M-24.0% | -$69.79M-40.7% | -$67.45M-41.2% | -$63.49M-25.6% | -$56.2M+4.2% | ||
| -$1.20-21.2% | -$1.22-38.6% | -$1.19-40.0% | -$1.12-24.4% | -$0.99+5.7% | ||
| -$78.14M-15.3% | -$78.85M-27.6% | -$77.38M-28.5% | -$74.31M-18.3% | -$67.79M+3.7% | ||
| -$78.76M-15.1% | -$79.47M-27.4% | -$77.99M-28.3% | -$74.93M-18.2% | -$68.4M+3.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Design Therapeutics, Inc. profitable?
- Design Therapeutics, Inc. is not currently profitable: it reported a net loss of $69.7M over the trailing twelve months, a -3663.7% net margin.
- What is Design Therapeutics, Inc.'s earnings per share?
- Design Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.20.
- Where does Design Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Design Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.